Compass Pathways Prepares Psilocybin Therapy for FDA Review

Compass Pathways is moving to file a rolling FDA submission for COMP360, its synthetic psilocybin therapy for treatment‑resistant depression, this quarter. CEO Kabir Nath said the company will “go slow before we go fast,” warning that early negative experiences could hurt the broader psychedelics market. The launch is aimed for early next year, but the company stresses a cautious rollout to protect patients and providers.

Rapid effects in trials

COMP360 differs from standard antidepressants, which take weeks and require daily dosing. In Phase‑3 trials, about a quarter of patients had a clinically meaningful response after one six‑hour supervised session. A second dose three weeks later raised the response rate to roughly 40%, and follow‑up data suggest benefits can last up to a year after two or three administrations.

Scientific questions remain about the role of the psychedelic experience and the integrity of blinded trials. Harvard professor Steven Hyman noted that patients often know they received the drug, complicating placebo control, and that it is unclear whether the subjective experience is essential for efficacy. Compass deliberately kept psychotherapy separate in its trials, finding that 80 % of session time was silence, but Hyman said the impact of therapy versus drug still needs study.

Regulatory and access concerns

The FDA is expected to require a risk‑evaluation and mitigation strategy (REMS) for COMP360, and Compass is investing in provider training and reimbursement mechanisms. The cost will include several hours of clinical monitoring, not just the medication itself. Nath said the company is working with insurers and the Centers for Medicare and Medicaid Services to secure coverage, while noting that a pricing benchmark might be similar to esketamine’s Spravato but without a firm figure.

Hyman warned that rushing psychedelics to market could damage credibility without rigorous research, responsible marketing, and long‑term safety data. He compared the field to cannabis, where early perceptions of safety were challenged by more potent products. The need for objective biomarkers remains, as current treatments rely heavily on subjective response, making it hard to predict which patients will benefit.